UMARY ACID HYALURONIC, 850 MG CAPLETS, 30-count bottle, UPC7502265120323

cGMP Deviations: the firm initiated a recall after notification from the distributor that product may be tainted with undeclared diclofenac and omeprazole, however there is no ana…

Recall #: D-0166-2025
Affected scope: 321 bottles
Initiated: November 14, 2024

Compiled from official public sources by the publisher. · Updated September 2026

Verify with FDA Drug →

View my saved recalls

Mxbbb recalled UMARY ACID HYALURONIC, 850 MG CAPLETS, 30-count bottle, UPC7502265120323 - a moderate-severity action.

UMARY ACID HYALURONIC, 850 MG CAPLETS, 30-count bottle, UPC7502265120323 was recalled by Mxbbb in January 1, 2025. Reason: cGMP Deviations: the firm initiated a recall after notification from the distributor that product may be tain…. Check the official notice for the remedy. Verify recall #D-0166-2025 with the FDA Drug before acting.

The recall

Mxbbb issued this moderate-severity FDA Drug recall-cGMP Deviations: the firm initiated a recall after notification from the distributor that product may be tain….

Moderate
severity level: Class II
classification: January 1, 2025
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0166-2025 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 1 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

UMARY ACID HYALURONIC, 850 MG CAPLETS, 30-count bottle, UPC7502265120323

Reason for recall

cGMP Deviations: the firm initiated a recall after notification from the distributor that product may be tainted with undeclared diclofenac and omeprazole, however there is no analytical data confirming that product distributed by the firm is tainted.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Moderate (Class II)
Status	Ongoing
Recall number	D-0166-2025
Date reported	January 1, 2025
Date initiated	November 14, 2024
Recalling firm	Mxbbb
Firm location	El Paso, TX
Affected scope	321 bottles
Distribution	Product was sold via Amazon Marketplace.

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-0166-2025) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

UMARY ACID HYALURONIC, 850 MG CAPLETS, 30-count bottle, UPC7502265120323. Recalled by Mxbbb. Units affected: 321 bottles.

Why was this product recalled? ▼

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on January 1, 2025. Severity: Moderate. Recall number: D-0166-2025.

Where was the recalled product distributed? ▼

Distribution: Product was sold via Amazon Marketplace..

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Moderate), closest by report date among other firms and states.

Duloxetine Delayed-Release Capsules USP, … 2025-01-01 Duloxetine Delayed-Release Capsules, USP,… 2025-01-01 Duloxetine Delayed-Release Capsules USP, … 2025-01-01 Duloxetine Delayed-Release Capsules, USP,… 2025-01-01

Similar Children & Baby Products · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

chlorproMAZINE Hydrochloride Tablets, USP… 2025-01-01 chlorproMAZINE Hydrochloride Tablets, USP… 2025-01-01 Euqee Wintergreen Essential Oils Recalled… 2025-01-02 SIG SAUER Recalls ROMEO5 Red Dot Firearm … 2025-01-08

Compare this recall with CLEAR EYES Maximum Itchy Eye Relief, 0.5 fl oz (15 mL) per … → · All Children & Baby Products recalls

This recall: FDA Drug, reported January 1, 2025. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026